Related Experiment Video
Updated: May 28, 2025

Isolation of Culturable Yeasts and Molds from Soils to Investigate Fungal Population Structure
Published on: May 27, 2022
Recent developments in Aspergillus fumigatus research: diversity, drugs, and disease
Nicole Kordana1, Angus Johnson1, Katherine Quinn1
1Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Abstract:
SUMMARYAdvances in modern medical therapies for many previously intractable human diseases have improved patient outcomes. However, successful disease treatment outcomes are often prevented due to invasive fungal infections caused by the environmental mold Aspergillus fumigatus. As contemporary antifungal therapies have not experienced the same robust advances as other medical therapies, defining mechanisms of A. fumigatus disease initiation and progression remains a critical research priority. To this end, the World Health Organization recently identified A. fumigatus as a research priority human fungal pathogen and the Centers for Disease Control has highlighted the emergence of triazole-resistant A. fumigatus isolates. The expansion in the diversity of host populations susceptible to aspergillosis and the complex and dynamic A. fumigatus genotypic and phenotypic diversity call for a reinvigorated assessment of aspergillosis pathobiological and drug-susceptibility mechanisms. Here, we summarize recent advancements in the field and discuss challenges in our understanding of A. fumigatus heterogeneity and its pathogenesis in diverse host populations.
Insights
Invasive fungal infections from Aspergillus fumigatus hinder medical treatment success. Research is prioritizing understanding this pathogen and its drug resistance to improve patient outcomes.
Area of Science:
- Mycology
- Infectious Diseases
- Medical Microbiology
Background:
- Modern medical therapies have advanced, yet invasive fungal infections caused by Aspergillus fumigatus remain a significant challenge.
- Contemporary antifungal therapies have lagged behind advances in other medical fields.
- Aspergillus fumigatus is recognized as a priority pathogen by the World Health Organization and exhibits emerging triazole resistance, as highlighted by the CDC.
Purpose of the Study:
- To summarize recent advancements in understanding Aspergillus fumigatus pathogenesis and heterogeneity.
- To address the critical need for defining mechanisms of Aspergillus fumigatus disease initiation and progression.
- To discuss challenges in comprehending Aspergillus fumigatus diversity and its impact on aspergillosis in various host populations.
Main Methods:
- Review of recent scientific literature on Aspergillus fumigatus.
- Analysis of genotypic and phenotypic diversity within Aspergillus fumigatus.
- Assessment of pathobiological mechanisms and drug-susceptibility in aspergillosis.
Main Results:
- Advances in understanding Aspergillus fumigatus pathogenesis are being made.
- Significant challenges remain in fully characterizing Aspergillus fumigatus heterogeneity.
- Emergence of triazole-resistant strains and diverse susceptible host populations complicates treatment.
Conclusions:
- A comprehensive understanding of Aspergillus fumigatus heterogeneity is crucial for combating invasive infections.
- Further research into pathobiological mechanisms and drug resistance is essential.
- Developing novel therapeutic strategies is necessary to overcome treatment limitations.
More Related Videos
09:52Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
15:01Confocal Laser Scanning Microscopy-Based Quantitative Analysis of Aspergillus fumigatus Conidia Distribution in Whole-Mount Optically Cleared Mouse Lung
Published on: September 18, 2021